Tag: over-current
-
Roche receives blood cancer drug blow after Gazyva trial fails to meet endpoint
Swiss drugmaker Roche said trials showed its new blood cancer drug Gazyva failed to deliver significant improvements over an older medicine in people with an aggressive type of blood cancer, a blow in its fight against competition from biosimilars. Gazyva did not significantly reduce the risk of disease worsening or death for people with previously…
-
Samsung Bioepis seeks Europe approval for its Humira copy
Biosimilars maker Samsung Bioepis, part of South Korea's top family-run conglomerate Samsung Group [SAGR.UL], said on Monday it is seeking regulatory approval in Europe to sell its copy of AbbVie Inc's rheumatoid arthritis drug Humira. Samsung Bioepis said in a statement the European Medicines Agency has accepted for review its application to sell its biosimilar…